6533b85efe1ef96bd12bfd37
RESEARCH PRODUCT
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
Daniele Di PaoloDi Marco VitoC. GavrilaGiovanni RaimondoPietro GattiMichele MilellaGiovanna D'andreaAntonio CraxìFilomena MoriscoMichele BaroneMartina FelderAlessio AghemoGiuseppe MazzellaGiovanna FattovichMario AngelicoTeresa SantantonioGiuseppina BrancaccioAntonina SmedileEleonora GrassiGiovanni SquadritoAntonio M. IppolitoAlessandra NardiNicola AndriulliAngelo AndriulliRaffaele CozzolongoMaria Rosa ValvanoVincenza CalvarusoMassimo FasanoPaolo Tundosubject
OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentdescription
none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 818 did not, with sustained virological response rates of 80.2% and 25.4%, respectively; interleukin-28B polymorphisms, fibrosis staging, gamma-glutamyl transferase, and viral load predicted sustained virological response. Assuming a <30% sustained virological response probability for not recommending Peg-interferon. +. ribavirin, 100 patients (25.6%) in the validation cohort were predicted a priori to fail this regimen. Assuming a â¥80% sustained virological response probability as a threshold to continue with Peg-interferon. +. ribavirin, 61 patients were predicted to obtain sustained virological response, and 55 of them (90.2%) eventually did. Conclusions: This model uses easily determined variables for a personalized estimate of the probability of sustained virological response with Peg-interferon. +. ribavirin, allowing to identify patients who may benefit from conventional therapy. © 2014 Editrice Gastroenterologica Italiana S.r.l. Andriulli, Angelo; Nardi, Alessandra; Di Marco, Vito; Ippolito, Antonio Massimo; Gavrila, Caius; Aghemo, Alessio; Di Paolo, Daniele; Squadrito, Giovanni; Grassi, Eleonora; Calvaruso, Vincenza; Valvano, Maria Rosa; Brancaccio, Giuseppina; Craxi, Antonio; Angelico, Mario; Raimondo, Giovanni; Milella, Michele; Morisco, Filomena; Fattovich, Giovanna; Felder, Martina; Smedile, Antonina; Fasano, Massimo; Santantonio, Teresa; Gatti, Pietro; Nicolaandriulli, Null; Tundo, Paolo; Barone, Michele; Cozzolongo, Raffaele; Giovanna D'andrea, Null; Mazzella, Giuseppe Andriulli, Angelo; Nardi, Alessandra; Di Marco, Vito; Ippolito, Antonio Massimo; Gavrila, Caius; Aghemo, Alessio; Di Paolo, Daniele; Squadrito, Giovanni; Grassi, Eleonora; Calvaruso, Vincenza; Valvano, Maria Rosa; Brancaccio, Giuseppina; Craxi, Antonio; Angelico, Mario; Raimondo, Giovanni; Milella, Michele; Morisco, Filomena; Fattovich, Giovanna; Felder, Martina; Smedile, Antonina; Fasano, Massimo; Santantonio, Teresa; Gatti, Pietro; Nicolaandriulli, Null; Tundo, Paolo; Barone, Michele; Cozzolongo, Raffaele; Giovanna D'andrea, Null; Mazzella, Giuseppe
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-09-01 | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |